ClinicalTrials.Veeva

Menu

Objective and Subjective Outcomes of a Trifocal IOL in Eyes With Different AL

P

Peking University

Status

Completed

Conditions

Myopia
Cataract
Satisfaction
Presbyopia
Lenses, Intraocular

Treatments

Other: AT LISA tri 839MP (Carl Zeiss Meditec AG)

Study type

Observational

Funder types

Other

Identifiers

NCT05431868
Trifocal&AL

Details and patient eligibility

About

This prospective cohort study enrolled patients with implantation of a trifocal IOL. Only one eye of each patient was enrolled. Eyes were devided into three groups according the axial length (AL), including the short AL group, the control group and the long AL group. Manifest refraction, uncorrected and distance-corrected visual acuity at different distances, contrast sensitivity, aberrations and IOL decentration were measured three months after surgery. Spectacle independence, adverse photic phenomena, overall satisfaction and life quality were assessed with a questionnaire.

Enrollment

61 patients

Sex

All

Ages

40+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Inclusion criteria were patients older than 40 years with significant bilateral or unilateral cataract seeking spectacle independence, with the AL between 21.00 to 30.00 mm, the prediction of postoperative corneal astigmatism less than 1.0 diopters (D), the angle kappa less than 0.50 mm, the corneal spherical aberration less than 0.5 μm and the corneal higher order aberration less than 0.5 μm.

Exclusion criteria

  • Exclusion criteria were eyes with serious intraoperative complications, irregular corneal astigmatism, corneal scarring, uveitis, glaucoma, pseudoexfoliation syndrome, macular degeneration or other retinal impairment, amblyopia or patients having difficulties with examinations or 3 months' follow-up.

Trial design

61 participants in 3 patient groups

the short AL group
Description:
Eyes with AL less than 22.50 mm were devided into the short AL group.
Treatment:
Other: AT LISA tri 839MP (Carl Zeiss Meditec AG)
the control group
Description:
Eyes with AL between 22.50 to 25.50 mm were devided into the control group.
Treatment:
Other: AT LISA tri 839MP (Carl Zeiss Meditec AG)
the long AL group
Description:
Eyes with AL more than 25.50 mm were devided into the long AL group.
Treatment:
Other: AT LISA tri 839MP (Carl Zeiss Meditec AG)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems